Please assess the completion status of the following clinical trial:

Trial Title: Memory Aid by Intranasal Insulin in Diabetes (MemAID)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 50-85 years old~* Able to walk for 6 minutes~* Diabetes type 2 (DM) group: diagnosis and treatment for type 2 DM with non-insulin oral or injectable agents~* Non-DM group with similar age range as the DM group, non-diabetic fasting plasma glucose (\<126 mg/dL) and hemoglobin A1c (HbA1c) (\<6.5%)~* Participants capable of providing informed consent~Exclusion Criteria:~* Type 2 DM treated with insulin (since 9/25/2017)~* Type 1 DM~* Intolerance to insulin~* History of severe hypoglycemia~* Participants who have \>1 asymptomatic and/or symptomatic episode of hypoglycemia (glucose \< 54 mg/dL) during finger stick or plasma glucose (cut off value since 6/11/2018)~* Acute medical condition that required either hospitalization or surgery within the past 6 months (e.g., severe hypoglycemia, malignancies, myocardial infarction,stroke)~* Liver or renal failure or transplant~* Dementia (Mini Mental State Examination \[MMSE\] scores ≤20)~* Current recreational drug or alcohol abuse~* Serious systemic disease that would interfere with conduction of clinical trial (mild forms of neurological conditions e.g. Parkinson's Disease, autonomic neuropathy etc. would be allowed)~* Magnetic Resonance Imaging (MRI) substudy in 40 DM patients only: claustrophobia and implants incompatible with 3-Tesla MRI~* Safety substudy in 20 IDDM patients only: Insulin-treated type 2 diabetics with a C-peptide of \<0.8 ng/mLd and fasting blood glucose \>150 mg/dL will be excluded even without history of hypoglycemia during finger stick measurements.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Type 2 Diabetes Mellitus - Insulin (Type: EXPERIMENTAL): 40 IU of regular human insulin once daily over 24 weeks
- Type 2 Diabetes Mellitus - Placebo (Type: PLACEBO_COMPARATOR): Intranasal sterile saline once daily over 24 weeks
- Control - Insulin (Type: EXPERIMENTAL): 40 IU of regular human insulin once daily over 24 weeks
- Control - Placebo (Type: PLACEBO_COMPARATOR): Intranasal sterile saline once daily over 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).